The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.
Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China.
Respirology. 2022 Apr;27(4):301-310. doi: 10.1111/resp.14191. Epub 2021 Nov 24.
Few head-to-head evaluations of immune responses to different vaccines have been reported.
Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or CoronaVac (n = 360) vaccines in Hong Kong were determined. An age-matched subgroup (BNT162b2 [n = 49] vs. CoronaVac [n = 49]) was tested for plaque reduction neutralization (PRNT) and spike-binding antibody and T-cell reactivity in peripheral blood mononuclear cells.
One month after the second dose of vaccine, BNT162b2 elicited significantly higher PRNT , PRNT , sVNT, spike receptor binding, spike N-terminal domain binding, spike S2 domain binding, spike FcR binding and antibody avidity levels than CoronaVac. The geometric mean PRNT titres in those vaccinated with BNT162b2 and CoronaVac vaccines were 251.6 and 69.45, while PRNT titres were 98.91 and 16.57, respectively. All of those vaccinated with BNT162b2 and 45 (91.8%) of 49 vaccinated with CoronaVac achieved the 50% protection threshold for PRNT Allowing for an expected seven-fold waning of antibody titres over 6 months for those receiving CoronaVac, only 16.3% would meet the 50% protection threshold versus 79.6% of BNT162b2 vaccinees. Age was negatively correlated with PRNT antibody titres. Both vaccines induced SARS-CoV-2-specific CD4 and CD8 T-cell responses at 1 month post-vaccination but CoronaVac elicited significantly higher structural protein-specific CD4 and CD8 T-cell responses.
Vaccination with BNT162b2 induces stronger humoral responses than CoronaVac. CoronaVac induces higher CD4 and CD8 T-cell responses to the structural protein than BNT162b2.
鲜有不同疫苗免疫应答的头对头评估报道。
测定香港接种两剂 BNT162b2（n=366）或科兴疫苗（n=360）的成年人的替代病毒中和试验（sVNT）抗体水平。对年龄匹配的亚组（BNT162b2 [n=49]与科兴 [n=49]）进行了外周血单个核细胞中蚀斑减少中和（PRNT）和刺突结合抗体及 T 细胞反应性检测。
接种第二剂疫苗后 1 个月，BNT162b2 诱导的 PRNT 、PRNT 、sVNT、刺突受体结合、刺突 N 末端域结合、刺突 S2 结构域结合、刺突 FcR 结合和抗体亲和力水平明显高于科兴。接种 BNT162b2 和科兴疫苗的几何平均 PRNT 滴度分别为 251.6 和 69.45，而 PRNT 滴度分别为 98.91 和 16.57。所有接种 BNT162b2 的人以及接种科兴的 45 人（91.8%）达到了 PRNT 的 50%保护阈值。考虑到接种科兴的人抗体滴度在 6 个月内预计会下降 7 倍，只有 16.3%的人会达到 50%的保护阈值，而 BNT162b2 疫苗接种者的这一比例为 79.6%。年龄与 PRNT 抗体滴度呈负相关。两种疫苗在接种后 1 个月均诱导了 SARS-CoV-2 特异性 CD4 和 CD8 T 细胞反应，但科兴疫苗诱导的结构蛋白特异性 CD4 和 CD8 T 细胞反应明显更高。
接种 BNT162b2 诱导的体液反应强于科兴。科兴诱导的结构蛋白特异性 CD4 和 CD8 T 细胞反应高于 BNT162b2。
